Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, or who were ineligible for, autologous stem cell transplantation (ASCT). Health-rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791579/
https://www.ncbi.nlm.nih.gov/pubmed/34644372
http://dx.doi.org/10.1182/bloodadvances.2021004970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791579/
https://www.ncbi.nlm.nih.gov/pubmed/34644372
http://dx.doi.org/10.1182/bloodadvances.2021004970

Ejemplares similares